The dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes

J. Wilson, Amir Nikooienejad, D. Robins, William Roell, J. Riesmeyer, A. Haupt, K. Duffin, M. Taskinen, G. Ruotolo • 9/15/2020

Abstract

To better understand the marked decrease in serum triglycerides observed with tirzepatide in patients with type 2 diabetes, additional lipoprotein‐related biomarkers were measured post hoc in available samples from the same study.

Citations: 102